Meyka AI API is live for developers.Start building.
Advertisement
Genomma Lab Internacional, S.A.B. de C.V.

Genomma Lab Internacional, S.A.B. de C.V. (GNMLF) Stock Competitors & Peer Comparison

See (GNMLF) competitors and their performances in Stock Market.

GNMLFPNK
HealthcareDrug Manufacturers - Specialty & Generic
$1.08
$0.00(0.00%)
U.S. Market opens in 55h 42m
Advertisement

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
GNMLF$1.08+0.00%1.1B10.80$0.10+4.04%
MKGAF$158.31-3.30%68.1B23.03$6.80+1.57%
MKKGY$31.32-3.48%68.1B23.03$1.36+1.64%
IPSEY$45.04+2.71%59.6B29.06$1.55+1.03%
TKPHF$30.47+0.00%48.1B40.63$0.75+4.28%
HLNCF$4.51+1.72%39.9B18.04$0.25+2.13%
TEVJF$30.34+0.50%35.3B22.64$1.34N/A
SDZNY$80.28-0.68%34.8B38.44$2.09+1.26%
TAIPY$14.00+16.67%18.1B82.35$0.17N/A
ESALY$61.51-2.11%17.6B20.54$3.00N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

GNMLF vs MKGAF Comparison June 2026

GNMLF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GNMLF stands at 1.1B. In comparison, MKGAF has a market cap of 68.1B. Regarding current trading prices, GNMLF is priced at $1.08, while MKGAF trades at $158.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GNMLF currently has a P/E ratio of 10.80, whereas MKGAF's P/E ratio is 23.03. In terms of profitability, GNMLF's ROE is +0.11%, compared to MKGAF's ROE of +0.08%. Regarding short-term risk, GNMLF is more volatile compared to MKGAF. This indicates potentially higher risk in terms of short-term price fluctuations for GNMLF.Check MKGAF's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions